CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to MBX

400 µg of MBX 2109 once-weekly by subcutaneous injection

Phase 2
MBX Biosciences, Inc. (MBX)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q2 '27
MBXPhase 2

400 µg of MBX 2109 once-weekly by subcutaneous injection Phase 2 Est. Readout

400 µg of MBX 2109 once-weekly by subcutaneous injection
Q2 2027~QSTALE
CT.gov
00%
Competitive Landscape

0 competitors in Hypoparathyroidism

View Full Landscape
Drug Information

Target Indication

Hypoparathyroidism

Clinical Trial

NCT06531941

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.